Skip to main content

Analysis: Louisiana Medical Marijuana Policy Stuck In Swamp

By, Melinda Deslatte

BATON ROUGE, La. (AP) — More than three years have passed since Louisiana lawmakers established a framework for dispensing medical marijuana in the state, and the timeline for patients to gain legal access to the drug keeps getting pushed back.

The new estimate for when therapeutic cannabis will be available is late January 2019, though the only state-sanctioned grower currently operating says that product release may be stalled until May 2019 instead, amid a disagreement with the Louisiana Department of Agriculture and Forestry.

State regulators took years to set the rules, license the doctors, and choose the pharmacies.

And now that the crop has been planted, new issues seem to continue emerging as the conservative Southern state grapples with how to restrict, yet offer medical marijuana.

Friction in particular seems to have emerged between GB Sciences, the grower chosen by the agricultural center at Louisiana State University (LSU), and the agriculture department over the interpretation of its rules regulating marijuana production.

Regulatory paperwork remains unfinished, and final production procedures remain uncertain. Questions abound about why Louisiana is taking so long to get the industry up and running when many other states offer models for doing the work.

Republican state Sen. Fred Mills, the pharmacist who crafted Louisiana’s medical cannabis laws, said the startup of a government-run program can take time to ensure patient safety and regulators’ comfort.

But he’s ready for patients to have access to medicinal marijuana.

“It does tear me up when I get people with a debilitating disease asking, ‘When is Louisiana going to have it ready?’ If I put myself in their position, I don’t think there’s any good explanation for them right now,” Mills said.

Nine dispensing pharmacies across the state have been chosen by the pharmacy board and are readying their locations. Forty doctors have been permitted by the medical licensing board to recommend medical cannabis to patients, and doctors have started consulting with people with chronic conditions eagerly awaiting legal cannabis.

Under a law passed in 2015 and tweaked since then, Louisiana is allowing medical cannabis to treat a long list of diseases and disorders, such as cancer, seizure disorders, epilepsy, glaucoma, post-traumatic stress disorder (PTSD) and Parkinson’s disease. Marijuana can be available as medicinal oils, capsules, liquids and topical applications, but cannot be sold in a smokable form.

Lawmakers created regulatory hurdles not seen in other states, such as deciding that only the LSU and Southern University agricultural centers can grow marijuana. Southern lags in starting its operation, taking longer to select contractor Advanced Biomedics.

Of the current crop planted by GB Sciences, the agriculture department estimates it will take up to six weeks to test samples for possible contaminants. The agency will do the testing in its own lab while continuing to search for an outside lab for future work.

John Davis, president of GB Sciences Louisiana, said the grower will submit a sample soon and a timeline worked out with Agriculture Commissioner Mike Strain should have testing done so medication is ready by the end of January.

But the agriculture department hasn’t signed off on regulatory paperwork required of GB Sciences, a process that started earlier in 2018. GB Sciences is operating in a temporary, smaller site until it receives approval to move into the main facility. Both sides say they’re working to resolve disagreements over the documents.

Still, another possible production disruption has emerged.

Davis said Strain’s office notified GB Sciences the procedures approved for the first crop of medical cannabis will have to be changed before the second crop. He said that could delay release of marijuana until May 2019 because GB Sciences doesn’t want to risk putting out a first batch of products without refills available.

“A patient who is undergoing some significant medical conditions does not need a break in their medication supply,” Davis said.

However, agriculture department attorney Tabitha Irvin said the agency hasn’t changed the rules. Instead, she said in a statement that GB Sciences, limited in production at its temporary site, was trying to use plants from another facility out of compliance with state law.

The agriculture department “has been tasked by the legislature as the regulatory agency to make sure the public gets a safe product and the (agency) and Commissioner Strain will not cut any corners,” Irvin said.

Original Article Source: https://www.marijuana.com/news/2018/10/analysis-louisiana-medical-marijuana-policy-stuck-in-swamp/

Comments

Popular posts from this blog

New York City Adds More Exceptions To Pre-Employment Marijuana Testing Ban

An ambitious campaign to decriminalize psychedelics in Washington, D.C., is one step closer to placing their measure on the November ballot with the formal submission of tens of thousands of voter signatures. Organizers have been scrambling for weeks to collect enough signatures from D.C. voters by Monday’s deadline amid historically difficult circumstances: a global pandemic, months of stay-at-home orders and protests over racism and police violence that filled the streets of the nation’s capital. But with the help of innovative signature-gathering techniques and allies flown in from across the country, advocates said they had successfully submitted upwards of 35,000 signatures—more than enough to qualify the initiative. If approved by voters, Initiative 81 would make enforcement of laws against plant- and fungus-based psychedelics among the “lowest law enforcement priorities” for the Metropolitan Police Department. It would not, however, legalize or reduce penalties for the subs

Charlotte Figi The Girl Who Inspired A CBD Movement Has Died At Age 13

Charlotte had recently been hospitalized due to pneumonia, breathing problems and seizures. She was treated as a likely case of Covid-19, her mother, Paige Figi, said Wednesday, although she tested negative for the virus. “Charlotte is no longer suffering. She is seizure-free forever,” a family friend wrote on Paige Figi’s Facebook page, announcing Charlotte’s death. “Thank you so much for all of your love.” Charlotte became a symbol of the possibilities of CBD after CNN Chief Medical Correspondent Dr. Sanjay Gupta told her story in the documentary “Weed.” In the film, Charlotte was shown to be a playful child who was overcome by horrific seizures, which were quelled with Charlotte’s Web, a marijuana strain named in her honor. Charlotte had Dravet syndrome, a rare form of epilepsy which was not controlled by medication. The Stanley brothers, marijuana growers in Colorado, were crossbreeding a strain of marijuana high in CBD and low in THC, its psychoactive ingredient. After Charlo

Virginia CBD Program Criticized As Multistate Medical Cannabis Operators Gain Edge

Seven companies are challenging a CBD licensing process in Virginia that resulted in multistate medical marijuana operators getting a majority of available licenses. The appeals called the process “wildly prejudicial.” Out of 51 applicants for five vertically integrated CBD and THC-A licenses, multistate operators received three, a situation that spurred the appeals, The Virginian-Pilot reported. Applicants filing the appeals complained the closed-meeting review process lacked fairness and transparency. One consultant to an applicant said the selections felt “predetermined.” The Virginia Board of Pharmacy reportedly sent information to the applicants in December explaining its selections, but some applicants weren’t satisfied. A board spokeswoman wrote in an email to the Pilot that the board “does not comment on pending litigation.” The five winning applicants , called “pharmaceutical processors,” have a year from winning the licenses to become operational. The multistate